About
Vita
Broad International BioPharmaceutical Professional with more than 20-years experience in Pharma Industry/Biotech, Medical Technology and Diagnostics focused in Oncology and Nephrology. Experience in various roles in Big Pharma/Bio Tech., Med.Tech. as well as Small and Medium Sized Companies. I have a „Hands-on-Mentality“, being persistent and get things done within tight timelines and within pre-set budgets. In 2013 I’ve initially started as Independent Consultant and Interim Manager.
Focus:- General and Country Management, „Global“
- Company Foundation & Growth
- Post Merger Integration
- Market Access Management
- Pre-Marketing and Launch of Drugs and Devices
- Set-up and Growth of new Business Areas, P&L Responsibility
- Strategic Business Development
- HEOR and Reimbursement Strategies
- Develop and Implement Sales & Marketing Strategies
- Consulting: Life Science & Drug Development
FOCUS & ATTRIBUTES
Check my FOCUS & ATTRIBUTES
General Management & Business Development
Commercial leadership including P&L responsibility & stakeholder management.
Strong Sales & Marketing Focus
Lead Sales & Marketing Department, Pre-Marketing & Launch a Block-Buster-Drug, Business Development, KOL-Management.
CRO Services Business
Consulting perspective „to see it with client´s eyes“.
Hands-on-Mentality
Hands-on-Mentality, strong communicator and negotiator on all levels.
References
Check my References
FOCUS & ATTRIBUTES
Check my FOCUS & ATTRIBUTES
- Big Pharma/Biotech/Medical Devices: AMGEN, GAMBRO, (Baxter), SIEMENS HEALTHINEERS, IQVIA
- Small/Medium Size Companies (SMC): PAREXEL, HIKMA, NANOSTRING TECHNOLOGIES Inc., NEW ONCOLOGY
- Start-Up: Foundation of EPN GmbH, the first non-US-subsidiary of AMERISOURCEBERGEN CORPORATION.
- USA (12-years), Sweden (6-years), MENA (5-years, Middle East North Africa).
- Diagnostics: Creating the new Business Model to promote the prognostic IVD-Test to realize personalized/individualized medicine for Early Breast Cancer (EBC).
- Successful Market Access with the IVD-Test in Oncology, Early Breast Cancer („EBC“) starting at University Clinics followed by out-patient facilities.
- Set-up a Key Opinion Leader (KOL) panel as expert group to promote the IVD-test on relevant congresses within scientific speeches..
- Successful integration of the IVD-Test in most relevant guidelines („St. Gallen Guidelines“, German „AGO-Guidelines, US „NCCN-Guidelines) as very important milestone within the Scientific Marketing for Market Access.
- Establish an „Early Market Access Program“ („EARP“) as intermediate solution before general reimbursement by statutory insurances within the German Health Care System. Overall responsibility, e.g. Acquisition of Key Centers, set-up of logistics, establishing an invoicing system for the members, Pathologists, Gynecologist/Breast Surgeon/Nanostring. Meet all internal and external compliance rules and receiving approval by the relevant stakeholder within Nanostring, e.g. Legal, Finance, Regulatory Affairs and Senior Management.
- Medical Technology – Nephrology, Hemodialysis: Ramp-up sales starting as Product Manager and being promoted to Group Product Manager of the most important product groups (Medical Devices & Drugs). Set-up the new Business Unit „Peritonealdialysis“ to expand revenues: Establishing and Grow this business as responsible Head of Marketing and Sales.
- Pharma/Biotechnology: AMGEN: Successful Pre-Marketing-Phase and Launch of the Blockbuster Product Aranesp®. Founding and establishing the Key Account Management for the Hospital (In-Patient) and Out-Patient-Sector. Drug Development Consulting: B-2-B: European Vice President Account Management: Set-Up the Account Management. Establishing Account Management Groups in : Berlin, Freiburg, Paris and Uxbridge/UK. Clients: Small, Midsize und „Big Pharma“ companies. Responsible including P&L for Europe but also for the multi-national company „LG“ as Vice President Europe Account Management.
- Diagnostics – Oncology: Launch Prosigna® Genexpression Assay for Early Breast Cancer („EBC“) as personalized Therapy to avoid unnecessary Chemotherapy. Market Access including P&L responsibility. Negotiation with and successful cooperation with AMGEN to promote Prosigna® on shared events in Germany.
- „B-2-B“ Model: Cooperative Sales Model: Establish a cooperative sales model for 13 Eastern European Countries within a „B-2-B“ approach in cooperation with an established and successful company in these countries.
- Responsible coordination to establish the mandatory document as basis for the reimbursement decision of the relevant authorities: Federal Joint Committee („G-BA“) as highest decisive body for reimbursement and the independent Institute for Quality and Effectiveness in Health Care („IQWiG-Institute) who evaluates the applications for reimbursement and is the consulting body of „G-BA“.
- Form and establish an external and independent team of specialists to support the internal departments: + Oncology (Gynecology) and Pathology + Leading Medicinal Law Firm + Internal US-Stakeholders: Medical Affairs, Legal, Regulatory Affairs & Research.
- Set-up and implement an „Early Access Reimbursement Programs (EARP)“, to grant access to the prognostic IVD-Test „Prosigna®“ for private but also for statutory patients. Establish all necessary documents within compliance, regulatory and legal regulations.
- Lobbying to include the new „nCounter-Technology“ &“Prosigna® in the relevant scientific Guidelines (AGO, NCCN, St. Gallen Guidelines).
- Big Pharma/Biotech/Medical Devices: AMGEN, GAMBRO, (Baxter), SIEMENS HEALTHINEERS, IQVIA
- Small/Medium Size Companies (SMC): PAREXEL, HIKMA, NANOSTRING TECHNOLOGIES Inc., NEW ONCOLOGY
- Start-Up: Foundation of EPN GmbH, the first non-US-subsidiary of AMERISOURCEBERGEN CORPORATION.
- USA (12-years), Sweden (6-years), MENA (5-years, Middle East North Africa).
Contact
Get In Touch Now
